Loading resource…

Hematology
MYC/BCL2 double-expressor lymphoma is a subtype of diffuse large B-cell lymphoma (DLBCL), marked by poor response to standard immunochemotherapy. This study involved 423 patients and was a randomized, double-blind, placebo-controlled, phase 3 clinical trial. The findings suggest that tucidinostat added to R-CHOP may improve event-free survival and complete response rates, although it also showed increased toxicity. Limitations include the study's single ethnic population and the need for further evaluation of maintenance tucidinostat.
No account needed